AU2012261237B2 - Individualized vaccines for cancer - Google Patents

Individualized vaccines for cancer Download PDF

Info

Publication number
AU2012261237B2
AU2012261237B2 AU2012261237A AU2012261237A AU2012261237B2 AU 2012261237 B2 AU2012261237 B2 AU 2012261237B2 AU 2012261237 A AU2012261237 A AU 2012261237A AU 2012261237 A AU2012261237 A AU 2012261237A AU 2012261237 B2 AU2012261237 B2 AU 2012261237B2
Authority
AU
Australia
Prior art keywords
cells
cancer
rna
tumor
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012261237A
Other languages
English (en)
Other versions
AU2012261237A1 (en
Inventor
Cedrik Britten
John Castle
Johannes Hendrikus DE GRAAF
Jan DIEKMANN
Mustafa DIKEN
Michael Koslowski
Sebastian Kreiter
Martin Lower
Tana Omokoko
Bernhard RENARD
Ugur Sahin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Biontech SE
Original Assignee
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH, Biontech SE filed Critical TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Publication of AU2012261237A1 publication Critical patent/AU2012261237A1/en
Application granted granted Critical
Publication of AU2012261237B2 publication Critical patent/AU2012261237B2/en
Assigned to BIONTECH AG, TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH reassignment BIONTECH AG Amend patent request/document other than specification (104) Assignors: BIONTECH AG, TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Priority to AU2017213515A priority Critical patent/AU2017213515B2/en
Assigned to TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, BIONTECH RNA PHARMACEUTICALS GMBH reassignment TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH Request for Assignment Assignors: TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-, BIONTECH AG
Priority to AU2019229434A priority patent/AU2019229434B2/en
Assigned to TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, BioNTech SE reassignment TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH Request for Assignment Assignors: BIONTECH RNA PHARMACEUTICALS GMBH, TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Priority to AU2022201275A priority patent/AU2022201275B2/en
Priority to AU2025267474A priority patent/AU2025267474A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Software Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
AU2012261237A 2011-05-24 2012-05-23 Individualized vaccines for cancer Active AU2012261237B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2017213515A AU2017213515B2 (en) 2011-05-24 2017-08-10 Individualized vaccines for cancer
AU2019229434A AU2019229434B2 (en) 2011-05-24 2019-09-13 Individualized vaccines for cancer
AU2022201275A AU2022201275B2 (en) 2011-05-24 2022-02-24 Individualized vaccines for cancer
AU2025267474A AU2025267474A1 (en) 2011-05-24 2025-11-14 Individualized vaccines for cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
AUPCT/EP2011/002576 2011-05-24
EP2012000006 2012-01-02
EPPCT/EP2012/000006 2012-01-02
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017213515A Division AU2017213515B2 (en) 2011-05-24 2017-08-10 Individualized vaccines for cancer

Publications (2)

Publication Number Publication Date
AU2012261237A1 AU2012261237A1 (en) 2013-11-14
AU2012261237B2 true AU2012261237B2 (en) 2017-06-01

Family

ID=46148823

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2012261237A Active AU2012261237B2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
AU2017213515A Active AU2017213515B2 (en) 2011-05-24 2017-08-10 Individualized vaccines for cancer
AU2019229434A Active AU2019229434B2 (en) 2011-05-24 2019-09-13 Individualized vaccines for cancer
AU2022201275A Active AU2022201275B2 (en) 2011-05-24 2022-02-24 Individualized vaccines for cancer
AU2025267474A Pending AU2025267474A1 (en) 2011-05-24 2025-11-14 Individualized vaccines for cancer

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2017213515A Active AU2017213515B2 (en) 2011-05-24 2017-08-10 Individualized vaccines for cancer
AU2019229434A Active AU2019229434B2 (en) 2011-05-24 2019-09-13 Individualized vaccines for cancer
AU2022201275A Active AU2022201275B2 (en) 2011-05-24 2022-02-24 Individualized vaccines for cancer
AU2025267474A Pending AU2025267474A1 (en) 2011-05-24 2025-11-14 Individualized vaccines for cancer

Country Status (23)

Country Link
US (3) US10738355B2 (enExample)
JP (6) JP6444171B2 (enExample)
CN (3) CN103608033B (enExample)
AU (5) AU2012261237B2 (enExample)
BR (1) BR112013029834A8 (enExample)
CA (1) CA2836494C (enExample)
DK (3) DK3892295T3 (enExample)
ES (4) ES2897656T3 (enExample)
FI (2) FI4223311T3 (enExample)
HR (3) HRP20230443T1 (enExample)
HU (3) HUE057608T2 (enExample)
LT (4) LT3892295T (enExample)
MX (3) MX386793B (enExample)
NZ (2) NZ730355A (enExample)
PL (2) PL4223311T3 (enExample)
PT (4) PT3473267T (enExample)
RS (3) RS62497B1 (enExample)
RU (1) RU2670745C9 (enExample)
SG (2) SG193553A1 (enExample)
SI (3) SI3473267T1 (enExample)
SM (3) SMT202100611T1 (enExample)
WO (1) WO2012159754A2 (enExample)
ZA (1) ZA201306944B (enExample)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8236503B2 (en) 2008-11-07 2012-08-07 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8685898B2 (en) 2009-01-15 2014-04-01 Imdaptive, Inc. Adaptive immunity profiling and methods for generation of monoclonal antibodies
CA2765949C (en) 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
WO2013059725A1 (en) 2011-10-21 2013-04-25 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3388535B1 (en) 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
ES2663234T3 (es) 2012-02-27 2018-04-11 Cellular Research, Inc Composiciones y kits para recuento molecular
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
MX354329B (es) 2012-05-08 2018-02-27 Adaptive Biotechnologies Corp Composiciones y metodos para medir y calibrar el error de amplificacion en reacciones de pcr multiple.
AU2013289939B2 (en) * 2012-07-12 2018-08-09 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
ES2737757T3 (es) 2012-09-28 2020-01-15 Univ Connecticut Identificación de epítopos protectores contra tumores para el tratamiento de cánceres
ES2749118T3 (es) 2012-10-01 2020-03-19 Adaptive Biotechnologies Corp Evaluación de la inmunocompetencia por la diversidad de los receptores de inmunidad adaptativa y caracterización de la clonalidad
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
AU2013351542B2 (en) * 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014093186A1 (en) * 2012-12-12 2014-06-19 Garvin Alex M Non-invasive detection of colorectal neoplasia using circular consensus sequencing
US9128861B2 (en) 2013-01-17 2015-09-08 Personalis, Inc. Methods and systems for genetic analysis
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
SG10201707394PA (en) * 2013-03-15 2017-10-30 Adaptive Biotechnologies Corp Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
KR102858313B1 (ko) * 2013-04-07 2025-09-10 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US20160186260A1 (en) * 2013-07-26 2016-06-30 Sequenta, Llc Cancer vaccination with antigen evolution
EP3480321B8 (en) 2013-08-28 2021-03-10 Becton, Dickinson and Company Massively parallel single cell analysis
WO2015031689A1 (en) 2013-08-30 2015-03-05 Personalis, Inc. Methods and systems for genomic analysis
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
CN105745528A (zh) 2013-10-07 2016-07-06 赛卢拉研究公司 用于以数字方式对阵列上的特征进行计数的方法和系统
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
ES2693217T3 (es) * 2013-12-02 2018-12-10 Personal Genome Diagnostics Inc. Método para evaluar variantes minoritarias en una muestra
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR102429859B1 (ko) * 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
HUE069802T2 (hu) 2014-04-23 2025-04-28 Modernatx Inc Nukleinsav vakcinák
US10017759B2 (en) * 2014-06-26 2018-07-10 Illumina, Inc. Library preparation of tagged nucleic acid
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック， インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
WO2016053339A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
ES2784343T3 (es) 2014-10-29 2020-09-24 Adaptive Biotechnologies Corp Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
WO2016070131A1 (en) 2014-10-30 2016-05-06 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US10697010B2 (en) * 2015-02-19 2020-06-30 Becton, Dickinson And Company High-throughput single-cell analysis combining proteomic and genomic information
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
MX2017010944A (es) 2015-02-26 2018-07-06 Sio2 Medical Products Inc Recipiente de polimero de cicloolefina con un revestimiento resistente a arañazos y antiestatico.
ES2836802T3 (es) 2015-02-27 2021-06-28 Becton Dickinson Co Códigos de barras moleculares espacialmente direccionables
EP4180535A1 (en) 2015-03-30 2023-05-17 Becton, Dickinson and Company Methods and compositions for combinatorial barcoding
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
CN107580632B (zh) 2015-04-23 2021-12-28 贝克顿迪金森公司 用于全转录组扩增的方法和组合物
RU2770447C2 (ru) * 2015-04-27 2022-04-18 Кэнсэр Ресерч Текнолоджи Лимитед Способ лечения рака
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
US11124823B2 (en) 2015-06-01 2021-09-21 Becton, Dickinson And Company Methods for RNA quantification
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017044574A1 (en) 2015-09-11 2017-03-16 Cellular Research, Inc. Methods and compositions for nucleic acid library normalization
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11623001B2 (en) 2015-10-12 2023-04-11 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
CN108604257B (zh) * 2015-10-12 2022-12-13 南托米克斯有限责任公司 产生特异性免疫治疗组合物及其相关核酸构建体的方法
CA3003090A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
CN105349533A (zh) * 2015-12-21 2016-02-24 生工生物工程（上海）股份有限公司 构建链特异性转录组文库的方法
CA3008437A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
US20190015491A1 (en) * 2016-01-08 2019-01-17 Vaccibody As Neoepitope rna cancer vaccine
EP3475434A4 (en) 2016-03-24 2020-07-29 Nantcell, Inc. SEQUENCES AND SEQUENCES ARRANGEMENTS FOR PRESENTATION OF NEO-EPITOPIA
PT3436048T (pt) 2016-03-31 2025-08-06 Biontech Us Inc Neoantigénios e métodos da sua utilização
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3445392A1 (en) * 2016-04-22 2019-02-27 CureVac AG Rna encoding a tumor antigen
WO2017192387A1 (en) 2016-05-02 2017-11-09 Cellular Research, Inc. Accurate molecular barcoding
AU2017260610B2 (en) 2016-05-04 2022-10-27 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
US11397882B2 (en) 2016-05-26 2022-07-26 Becton, Dickinson And Company Molecular label counting adjustment methods
MX2018014602A (es) * 2016-05-27 2019-06-10 Etubics Corp Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
KR20190027834A (ko) * 2016-07-13 2019-03-15 백심 아게 암 면역요법용 dna 백신을 제조하기 위한 방법
WO2018015433A2 (en) * 2016-07-20 2018-01-25 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
EP3516400B1 (en) 2016-09-26 2023-08-16 Becton, Dickinson and Company Measurement of protein expression using reagents with barcoded oligonucleotide sequences
EP4628595A3 (en) 2016-11-08 2025-11-05 Becton, Dickinson and Company Methods for cell label classification
CN109952612B (zh) 2016-11-08 2023-12-01 贝克顿迪金森公司 用于表达谱分类的方法
US20190321481A1 (en) 2016-11-11 2019-10-24 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
CN108090325B (zh) * 2016-11-23 2022-01-25 中国科学院昆明动物研究所 一种应用β-稳定性分析单细胞测序数据的方法
ES2961580T3 (es) 2017-01-13 2024-03-12 Cellular Res Inc Revestimiento hidrófilo de canales de fluidos
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
CA3050109A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
MX2019009070A (es) * 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
EP3576751A4 (en) * 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
US11319583B2 (en) 2017-02-01 2022-05-03 Becton, Dickinson And Company Selective amplification using blocking oligonucleotides
EP3580561B1 (en) * 2017-02-12 2023-11-01 BioNTech US Inc. Hla-based methods and compositions and uses thereof
JP7249287B2 (ja) 2017-03-31 2023-03-30 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
IL270132B2 (en) 2017-04-24 2024-12-01 Nantcell Inc Neoepitope vectors and methods for them
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3621629B1 (en) 2017-05-11 2025-12-24 Theralase Technologies Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
US12072337B2 (en) 2017-05-30 2024-08-27 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
CN110719959B (zh) 2017-06-05 2021-08-06 贝克顿迪金森公司 针对单细胞的样品索引
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019005764A1 (en) 2017-06-27 2019-01-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center MHC-I GENOTYPE LIMITING THE ONCOGEN MUTATIONAL LANDSCAPE
MX2020000414A (es) * 2017-07-12 2020-09-28 Nouscom Ag Composicion de vacuna de neoantigeno para el tratamiento del cancer.
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US12504380B2 (en) 2017-09-25 2025-12-23 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US20200354730A1 (en) * 2017-11-27 2020-11-12 Nantcell, Inc. Improved Yeast Polytope Vaccine Compositions And Methods
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019105485A1 (zh) * 2017-12-01 2019-06-06 上海桀蒙生物技术有限公司 个性化癌症疫苗的制备方法
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CA3083792A1 (en) * 2017-12-18 2019-06-27 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
CN111492068B (zh) 2017-12-19 2025-03-21 贝克顿迪金森公司 与寡核苷酸相关联的颗粒
CA3087537A1 (en) 2018-01-04 2019-07-11 Jan-willem THEUNISSEN Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
JP7437310B2 (ja) * 2018-03-14 2024-02-22 コーニンクレッカ フィリップス エヌ ヴェ Ｒｎａシーケンシングデータの転写発現レベルを解釈するために局所的なユニークな特徴を使用するシステム及び方法
US12462935B2 (en) * 2018-03-30 2025-11-04 Nucleix Ltd. Deep learning-based methods, devices, and systems for prenatal testing
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
WO2019213237A1 (en) 2018-05-03 2019-11-07 Becton, Dickinson And Company Molecular barcoding on opposite transcript ends
AU2019262048B2 (en) 2018-05-03 2025-09-04 Becton, Dickinson And Company High throughput multiomics sample analysis
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
JP2021525549A (ja) * 2018-05-25 2021-09-27 ザ ウィスター インスティテュート 腫瘍特異的ネオ抗原およびその使用方法
CN108897986B (zh) * 2018-05-29 2020-11-27 中南大学 一种基于蛋白质信息的基因组序列拼接方法
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
KR20210038886A (ko) * 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
CA3106562A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
SG11202101965QA (en) 2018-09-27 2021-04-29 Vaccibody As Method for selecting neoepitopes
WO2020072380A1 (en) 2018-10-01 2020-04-09 Cellular Research, Inc. Determining 5' transcript sequences
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
CA3118947A1 (en) * 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
EP3877520B1 (en) 2018-11-08 2025-03-19 Becton, Dickson And Company Whole transcriptome analysis of single cells using random priming
US20210379170A1 (en) * 2018-11-15 2021-12-09 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
US11492660B2 (en) 2018-12-13 2022-11-08 Becton, Dickinson And Company Selective extension in single cell whole transcriptome analysis
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
GB201821205D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
US20220093217A1 (en) * 2019-01-08 2022-03-24 Caris Mpi, Inc. Genomic profiling similarity
TW202515617A (zh) * 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
US11371076B2 (en) 2019-01-16 2022-06-28 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
US11661631B2 (en) 2019-01-23 2023-05-30 Becton, Dickinson And Company Oligonucleotides associated with antibodies
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3924506A1 (en) 2019-02-14 2021-12-22 Becton Dickinson and Company Hybrid targeted and whole transcriptome amplification
WO2020167240A1 (en) * 2019-02-15 2020-08-20 Rjan Holdng Ab Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine
CN113784725A (zh) * 2019-03-01 2021-12-10 弗洛制药公司 个性化癌症疫苗的设计、制造和用途
JP7722661B2 (ja) 2019-03-13 2025-08-13 東洋紡株式会社 核酸の生成および増幅
US11965208B2 (en) 2019-04-19 2024-04-23 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
KR20220016137A (ko) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 변형된 아데노바이러스
CN114051534B (zh) 2019-07-22 2025-02-21 贝克顿迪金森公司 单细胞染色质免疫沉淀测序测定
CN110277135B (zh) * 2019-08-10 2021-06-01 杭州新范式生物医药科技有限公司 一种基于预期疗效选择个体化肿瘤新抗原的方法和系统
EP4031562A4 (en) * 2019-09-20 2023-11-01 University of Florida Research Foundation, Incorporated DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
US12331131B2 (en) * 2019-09-20 2025-06-17 Navi Bio-Therapeutics, Inc. Personalized cancer immunotherapy
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN114945987A (zh) 2019-11-05 2022-08-26 佩索纳里斯公司 从单一样品预估肿瘤纯度
US11773436B2 (en) 2019-11-08 2023-10-03 Becton, Dickinson And Company Using random priming to obtain full-length V(D)J information for immune repertoire sequencing
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
US11649497B2 (en) 2020-01-13 2023-05-16 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and RNA
US12188010B2 (en) 2020-01-29 2025-01-07 Becton, Dickinson And Company Barcoded wells for spatial mapping of single cells through sequencing
EP4111168A1 (en) 2020-02-25 2023-01-04 Becton Dickinson and Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
AU2021236763A1 (en) 2020-03-20 2022-10-06 Lonza Sales Ag Extracellular vesicles for therapy
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
CN115605614A (zh) 2020-05-14 2023-01-13 贝克顿迪金森公司（Us） 用于免疫组库谱分析的引物
EP4158014A2 (en) 2020-05-26 2023-04-05 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
EP4158055B1 (en) 2020-06-02 2024-03-27 Becton, Dickinson and Company Oligonucleotides and beads for 5 prime gene expression assay
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
US12391940B2 (en) 2020-07-31 2025-08-19 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20230323431A1 (en) * 2020-08-31 2023-10-12 World Biotech Regenerative Medical Group Limited Personalized Immunogenic Compositions and Methods for Producing and Using Same
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
US11739443B2 (en) 2020-11-20 2023-08-29 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
KR20230142704A (ko) 2020-12-14 2023-10-11 바이오엔테크 유에스 인크. 암 면역요법을 위한 조직 특이적 항원
CN116685850A (zh) 2020-12-15 2023-09-01 贝克顿迪金森公司 单细胞分泌组分析
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CA3227081A1 (en) 2021-08-24 2023-03-02 Irena RABE In vitro transcription technologies
US12297508B2 (en) 2021-10-05 2025-05-13 Personalis, Inc. Customized assays for personalized cancer monitoring
WO2023085232A1 (ja) 2021-11-10 2023-05-19 東洋紡株式会社 改良されたライブラリー調製方法
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
CN114181287B (zh) * 2021-12-10 2023-09-19 商丘美兰生物工程有限公司 一种dna病毒疫苗的制备方法
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114410778B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
KR20230130804A (ko) * 2022-03-04 2023-09-12 (주)큐리진 순환종양세포 검출을 위한 아데노바이러스 5/3 형
EP4253550A1 (en) 2022-04-01 2023-10-04 GenCC GmbH 6 Co. KG Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
CN120225219A (zh) * 2022-09-23 2025-06-27 生物技术欧洲股份公司 用于递送肝期抗原的组合物及相关方法
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
CN120584195A (zh) 2023-01-26 2025-09-02 东洋纺株式会社 源自核糖体rna的逆转录的抑制
WO2024231973A1 (ja) * 2023-05-08 2024-11-14 株式会社日立製作所 情報処理装置
WO2025024337A1 (en) * 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025064850A1 (en) * 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025191449A1 (en) 2024-03-11 2025-09-18 Instadeep Ltd Systems and methods for machine learning-based genome annotation
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025207807A1 (en) * 2024-03-27 2025-10-02 The University Of Florida Research Foundation, Inc. Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2025257735A1 (en) 2024-06-10 2025-12-18 BioNTech SE Systems and methods for machine learning model-based prediction of immune response
CN119049567B (zh) * 2024-08-08 2025-07-22 笙源生命科技(安吉)有限公司 一种基于单细胞测序区分嵌合体动物模型中异种杂交样本遗传物质和细胞物种来源的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040156A1 (en) * 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
WO1999034015A2 (en) * 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
CA2271388C (en) 1996-09-13 2007-11-06 The School Of Pharmacy, University Of London Liposomes encapsulating polynucleotides operatively coding for immunogenic polypeptides
EP0930887B1 (en) * 1996-10-11 2002-12-18 The Regents of the University of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
AU743066B2 (en) 1997-11-06 2002-01-17 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO1999034014A2 (en) 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
CA2345440A1 (en) 1998-10-05 2000-04-13 Charles A. Nicolette Genes differentially expressed in cancer cells to design cancer vaccines
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
DE60042556D1 (de) 1999-09-16 2011-02-10 Eisai Inc Für polyepitop-polypeptide kodierende nukleinsäuren
JP2004500047A (ja) * 1999-10-20 2004-01-08 ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン キメラ免疫原性組成物およびこれらをコードする核酸
EP1261704B1 (en) 1999-11-30 2009-07-01 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001047541A1 (en) 1999-12-28 2001-07-05 Epimmune, Inc. Optimized minigenes and peptides encoded thereby
US20040052763A1 (en) 2000-06-07 2004-03-18 Mond James J. Immunostimulatory RNA/DNA hybrid molecules
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
ATE464317T1 (de) 2001-06-05 2010-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt für die gentherapie
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
WO2003046189A1 (en) 2001-11-26 2003-06-05 The University Of Queensland Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2002254010A1 (en) * 2002-02-19 2003-09-09 Genzyme Corporation Par-3 compounds for therapy and diagnosis and methods for using same
WO2003078595A2 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
PT1512014E (pt) 2002-06-13 2009-11-10 Merck Patent Gmbh Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
PT2286794T (pt) 2003-10-15 2016-07-13 Syncore Biotechnology Co Ltd Uso de lipossomas catiónicos contendo placlitaxel
WO2005040816A1 (en) 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of therapy
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
EP1838342A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2007101227A2 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
WO2007106545A2 (en) 2006-03-13 2007-09-20 Veridex, Llc Propagation of primary cells
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
NZ588183A (en) 2008-03-24 2012-05-25 4Sc Discovery Gmbh Novel substituted imidazoquinolines
BRPI0910464B1 (pt) 2008-04-17 2021-08-10 Pds Biotechnology Corporation Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica
JP5268444B2 (ja) * 2008-06-23 2013-08-21 株式会社日立ハイテクノロジーズ 単分子リアルタイムシーケンス装置，核酸分析装置及び単分子リアルタイムシーケンス方法
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US20110195090A1 (en) 2008-10-11 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Method of making a vaccine
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
RS59369B1 (sr) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizovane vakcine protiv kancera
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
WO2013106496A1 (en) 2012-01-10 2013-07-18 modeRNA Therapeutics Methods and compositions for targeting agents into and across the blood-brain barrier
WO2013124701A2 (en) 2012-02-20 2013-08-29 Universita' Degli Studi Di Milano New homo- and heterodimeric smac mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
AU2013289939B2 (en) 2012-07-12 2018-08-09 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
BR122019025678B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Composições que compreendem ácido nucleico que codifica uma proteína de edição gênica
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
KR102858313B1 (ko) 2013-04-07 2025-09-10 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
US9950065B2 (en) 2013-09-26 2018-04-24 Biontech Rna Pharmaceuticals Gmbh Particles comprising a shell with RNA
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170007776A1 (en) 2014-02-05 2017-01-12 Biontech Ag Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
HUE069802T2 (hu) 2014-04-23 2025-04-28 Modernatx Inc Nukleinsav vakcinák
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
DK4023755T5 (da) 2014-12-12 2024-07-29 CureVac SE Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
JP6907116B2 (ja) 2014-12-30 2021-07-21 キュアバック アーゲー 人工核酸分子
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040156A1 (en) * 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
WO1999034015A2 (en) * 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FAWCETT T., "An introduction to ROC analysis", Pattern Recognition Letters, 2006, vol 27, pages 861-874 *
GJERTSEN M. K., et al, "Mutated ras peptides as vaccines in immunotherapy of cancer", Vox Sanguinis, 1998, vol 74, pages 489-495 *
Kreiter et al (2011) Current Opinion in Immunology, June, 23(3):399-406, published online 13 April 2011 *
Novellino et al (2005) Cancer Immunology, Immunotherapy, March, 54(3):187-207 *
Pilla et al (2009) Expert Opinion on Biological Therapy, August, 9(8):1043-1055 *
RAHMA O. E., et al, "A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma", Journal of Translational Medicine, 2010, vol 8, pages 1-9 *
Rammensee et al (2008) "Cancer Vaccines: Some Basic Considerations", In: Ginsburg & Willard (Eds.), Genomic and Personalized Medicine, pp 573-589, Elsevier/Academic Press *
SJÖBLOM T., et al, "The consensus coding sequences of human breast and colorectal cancers", Science, 2006, vol 314, pages 268-274 *
Smith et al (2001) Clinical Cancer Research, December, 7(12):4253-4261 *

Also Published As

Publication number Publication date
RU2670745C2 (ru) 2018-10-25
HUE046152T2 (hu) 2020-02-28
RU2013157150A (ru) 2015-06-27
LT2714071T (lt) 2019-10-10
AU2017213515B2 (en) 2019-07-04
MX2020011767A (es) 2020-11-24
SMT202300161T1 (it) 2023-07-20
SMT202100611T1 (it) 2022-01-10
BR112013029834A2 (pt) 2016-12-06
FI4223311T3 (fi) 2025-08-12
AU2019229434A1 (en) 2019-10-03
WO2012159754A2 (en) 2012-11-29
LT3473267T (lt) 2021-11-25
JP2025109722A (ja) 2025-07-25
PT4223311T (pt) 2025-08-21
BR112013029834A8 (pt) 2019-05-07
AU2012261237A1 (en) 2013-11-14
JP2023083289A (ja) 2023-06-15
ES2746233T8 (es) 2020-03-13
HRP20230443T1 (hr) 2023-09-15
PT2714071T (pt) 2019-09-30
JP6456888B2 (ja) 2019-01-23
HUE062102T2 (hu) 2023-09-28
JP2014523406A (ja) 2014-09-11
RS67093B1 (sr) 2025-09-30
CN111286537A (zh) 2020-06-16
AU2025267474A1 (en) 2026-01-08
NZ742420A (en) 2022-10-28
PL4223311T3 (pl) 2025-09-08
SI3473267T1 (sl) 2022-01-31
NZ617217A (en) 2016-04-29
DK4223311T3 (da) 2025-08-25
MX386793B (es) 2025-03-19
US20210164034A1 (en) 2021-06-03
SG193553A1 (en) 2013-10-30
CA2836494C (en) 2023-01-03
SI4223311T1 (sl) 2025-11-28
AU2019229434B2 (en) 2021-12-16
CN103608033A (zh) 2014-02-26
LT4223311T (lt) 2025-09-25
SI3892295T1 (sl) 2023-09-29
PT3892295T (pt) 2023-06-01
JP6444171B2 (ja) 2018-12-26
ES2897656T3 (es) 2022-03-02
US20220282322A1 (en) 2022-09-08
JP2020128423A (ja) 2020-08-27
CN105999250B (zh) 2020-03-10
US20140178438A1 (en) 2014-06-26
SMT202500304T1 (it) 2025-09-12
AU2022201275B2 (en) 2025-08-14
RU2670745C9 (ru) 2018-12-13
CA2836494A1 (en) 2012-11-29
RS62497B1 (sr) 2021-11-30
ES3038443T3 (en) 2025-10-13
US11248264B2 (en) 2022-02-15
FI3892295T3 (fi) 2023-05-10
ES2746233T3 (es) 2020-03-05
PT3473267T (pt) 2021-11-02
US10738355B2 (en) 2020-08-11
DK3892295T3 (da) 2023-05-15
ZA201306944B (en) 2015-02-25
HRP20211595T1 (hr) 2022-01-21
WO2012159754A3 (en) 2013-06-27
JP2019050831A (ja) 2019-04-04
DK2714071T3 (da) 2019-09-16
ES2946072T3 (es) 2023-07-12
PL3892295T3 (pl) 2023-07-24
AU2017213515A1 (en) 2017-08-31
NZ718326A (en) 2020-05-29
JP2017018129A (ja) 2017-01-26
MX360823B (es) 2018-11-16
MX2013013659A (es) 2014-02-27
NZ730355A (en) 2022-10-28
HUE057608T2 (hu) 2022-06-28
CN103608033B (zh) 2016-06-15
SG10201911616QA (en) 2020-01-30
LT3892295T (lt) 2023-07-10
HRP20250981T1 (hr) 2025-10-24
CN105999250A (zh) 2016-10-12
RS64230B1 (sr) 2023-06-30
JP7297715B2 (ja) 2023-06-26
AU2022201275A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
AU2022201275B2 (en) Individualized vaccines for cancer
US20230190898A1 (en) Individualized vaccines for cancer
EP3892295B1 (en) Individualized vaccines for cancer
HK40098119A (en) Individualized vaccines for cancer
HK40120924A (en) Individualized vaccines for cancer
HK40006796A (en) Individualized vaccines for cancer
NZ617217B2 (en) Individualized vaccines for cancer
HK40052764B (en) Individualized vaccines for cancer
HK40052764A (en) Individualized vaccines for cancer
HK40000563B (en) Individualized vaccines for cancer
HK40000563A (en) Individualized vaccines for cancer
NZ718326B2 (en) Individualized vaccines for cancer
HK1191241A (en) Individualized vaccines for cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATS

Free format text: FORMER NAME(S): TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH ; BIONTECH AG

Owner name: BIONTECH AG

Free format text: FORMER NAME(S): TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH ; BIONTECH AG

PC1 Assignment before grant (sect. 113)

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAE

Free format text: FORMER APPLICANT(S): TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-; BIONTECH AG

Owner name: BIONTECH RNA PHARMACEUTICALS GMBH

Free format text: FORMER APPLICANT(S): TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-; BIONTECH AG

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH

Free format text: FORMER OWNER(S): TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH; BIONTECH RNA PHARMACEUTICALS GMBH

Owner name: BIONTECH SE

Free format text: FORMER OWNER(S): TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH; BIONTECH RNA PHARMACEUTICALS GMBH